Skye Bioscience Inc. announced interim 52-week data from the extension phase of its Phase 2a CBeyond proof-of-concept study evaluating nimacimab, a peripherally-restricted CB1 inhibitor antibody, in combination with semaglutide for obesity and metabolic disorders. The results showed a 22.3% total weight loss at 52 weeks for the combination of nimacimab (200 mg) and semaglutide (2.4 mg), with no plateau observed, suggesting the potential for continued efficacy beyond one year and at higher nimacimab doses. The combination also demonstrated a reduction in weight regain during a 13-week treatment interruption, with participants regaining 17.8% of weight lost compared to 37.3% for semaglutide alone. The safety and tolerability profile remained strong, with no serious adverse events reported. Full topline data, including nimacimab monotherapy results and off-therapy follow-up, are expected to be reported in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9646830) on February 02, 2026, and is solely responsible for the information contained therein.